该USP1抑制剂KSQ-4279克服了PARP抑制剂在同源重组缺陷瘤的抵抗
Louise Cadzow1, Jehrod Brenneman1, Erica Tobin1
1KSQ Therapeutics, Lexington, Massachusetts.
Cancer research
|October 15, 2024
概括
一种名为KSQ-4279的新药向USP1 (泛基素特异性酶-1),以克服BRCA突变瘤中对PARP抑制剂的耐药性. 这种组合疗法在治疗难以治疗的癌症方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 缺陷的DNA修复途径,像同源重组 (HR) 缺陷,是瘤进化和治疗耐药性的关键驱动因素.
- PARP 抑制剂在HR缺陷的瘤中有效 (例如,BRCA1/2突变),但耐药性仍然是一个重大的临床挑战.
- 具有DNA修复缺陷的瘤通常会对剩余的修复机制产生依赖.
研究的目的:
- 在PARP抑制剂耐药瘤中确定新的治疗点.
- 开发和评估一种强大且有选择性的无素特异性酶-1 (USP1) 抑制剂,以克服耐药性.
- 在临床前模型中,评估将USP1抑制剂与PARP抑制剂结合的疗效.
主要方法:
- 确定USP1作为BRCA突变和HR缺陷瘤中的关键依赖.
- 开发KSQ-4279,一个第一类强效和选择性的USP1抑制剂.
- 使用患者衍生PARP耐药模型,对KSQ-4279与PARP抑制剂结合进行临床前测试.
主要成果:
- KSQ-4279证明了USP1.1的强大和选择性抑制.
- 在临床前模型中,KSQ-4279和PARP抑制剂的组合被很好地容忍.
- 在用组合疗法治疗的患者衍生PARP耐药模型中观察到持久的瘤回归.
结论:
- 在BRCA突变和HR缺陷的瘤中,USP1是关键的依赖.
- 像KSQ-4279这样的USP1抑制剂是克服PARP抑制剂耐药性的有希望的策略.
- 与USP1和PARP抑制剂的联合治疗需要对BRCA突变/HR缺陷瘤进行进一步的临床研究.
更多相关视频
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
3.9K
09:58Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
13.7K
相关概念视频
02:53Conservative Site-specific Recombination and Phase Variation
5.9K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
5.9K
02:37Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K